Trade Report: The Swiss National Bank Invests $468,000 in Loxo Oncology Inc. (LOXO)

The Swiss National Bank Invests $468,000 in Loxo Oncology Inc. (LOXO)

Swiss National Bank purchased a new position in shares of Loxo Oncology Inc. (NASDAQ:LOXO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,200 shares of the biopharmaceutical company’s stock, valued at approximately $468,000. Swiss National Bank owned about 0.10% of Loxo Oncology as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Strs Ohio increased its position in Loxo Oncology by 8.7% in the second quarter. Strs Ohio now owns 11,200 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 900 shares during the period. California State Teachers Retirement System increased its position in Loxo Oncology by 42.9% in the second quarter. California State Teachers Retirement System now owns 27,964 shares of the biopharmaceutical company’s stock worth $648,000 after buying an additional 8,392 shares during the period. Alps Advisors Inc. increased its position in Loxo Oncology by 39.1% in the second quarter. Alps Advisors Inc. now owns 30,015 shares of the biopharmaceutical company’s stock worth $696,000 after buying an additional 8,437 shares during the period. Geode Capital Management LLC increased its position in Loxo Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 57,068 shares of the biopharmaceutical company’s stock worth $1,560,000 after buying an additional 2,126 shares during the period. Finally, UBS Asset Management Americas Inc. purchased a new position in Loxo Oncology during the first quarter worth $2,197,000. Institutional investors own 95.46% of the company’s stock.

Loxo Oncology Inc. (NASDAQ:LOXO) traded down 0.24% during mid-day trading on Monday, hitting $21.06. The company had a trading volume of 48,925 shares. The firm’s market capitalization is $456.24 million. Loxo Oncology Inc. has a 1-year low of $16.36 and a 1-year high of $35.00. The company has a 50 day moving average of $25.77 and a 200 day moving average of $25.33.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.14. Analysts predict that Loxo Oncology Inc. will post ($2.91) earnings per share for the current fiscal year.

A number of research analysts have weighed in on LOXO shares. Cowen and Company reiterated a “buy” rating on shares of Loxo Oncology in a report on Wednesday, July 13th. Zacks Investment Research upgraded Loxo Oncology from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Saturday, July 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $29.60.

In other Loxo Oncology news, Director Keith T. Flaherty sold 14,500 shares of the firm’s stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $30.00, for a total value of $435,000.00. Following the completion of the sale, the director now owns 45,982 shares of the company’s stock, valued at $1,379,460. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director David P. Bonita sold 447,857 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $26.96, for a total transaction of $12,074,224.72. The disclosure for this sale can be found here. 44.40% of the stock is currently owned by corporate insiders.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Related posts

Leave a Comment